Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-18-007566
Filing Date
2018-05-21
Accepted
2018-05-21 16:19:51
Documents
56
Period of Report
2018-03-31

Document Format Files

Seq Description Document Type Size
1 form10q.htm 10-Q 1094097
2 ex31-1.htm EX-31.1 18700
3 ex31-2.htm EX-31.2 17090
4 ex32-1.htm EX-32.1 7540
5 ex32-2.htm EX-32.2 7418
  Complete submission text file 0001493152-18-007566.txt   6063138

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE rspi-20180331.xml EX-101.INS 1125548
7 XBRL SCHEMA FILE rspi-20180331.xsd EX-101.SCH 66826
8 XBRL CALCULATION FILE rspi-20180331_cal.xml EX-101.CAL 41302
9 XBRL DEFINITION FILE rspi-20180331_def.xml EX-101.DEF 308319
10 XBRL LABEL FILE rspi-20180331_lab.xml EX-101.LAB 457092
11 XBRL PRESENTATION FILE rspi-20180331_pre.xml EX-101.PRE 365784
Mailing Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452
Business Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452 (201) 444-4947
RespireRx Pharmaceuticals Inc. (Filer) CIK: 0000849636 (see all company filings)

EIN.: 330303583 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-16467 | Film No.: 18849846
SIC: 2834 Pharmaceutical Preparations